Janice Rivera
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 130 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,080, more than ten times the $20 reported in 2023.
Across 130 payments — averaging $20.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$600
- Pfizer$309
- Lundbeck LLC$212
- Eisai Inc.$166
- UCB, Inc.$165
- Argenx US, Inc.$150
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,665100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 29 | $600 |
| Pfizer | 20 | $309 |
| Lundbeck LLC | 12 | $212 |
| Eisai Inc. | 7 | $166 |
| UCB, Inc. | 5 | $165 |
| Argenx US, Inc. | 9 | $150 |
| Vanda Pharmaceuticals Inc. | 7 | $131 |
| Lilly USA, LLC | 5 | $116 |
| Catalyst Pharmaceuticals, Inc. | 4 | $94 |
| TG Therapeutics, Inc. | 3 | $88 |
| Novartis | 4 | $86 |
| Amgen | 3 | $78 |
| Amneal Pharmaceuticals LLC | 3 | $60 |
| Merz Pharmaceuticals, LLC | 2 | $55 |
| Neurelis, Inc. | 3 | $54 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| SK Life Science, Inc. | 2 | $50 |
| Jazz Pharmaceuticals Inc. | 2 | $37 |
| Nevro Corp. | 1 | $28 |
| Genentech USA, Inc. | 1 | $27 |
| Boston Scientific | 1 | $25 |
| Biogen | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Aucta Pharmaceuticals, Inc. | 1 | $15 |
| C2n Diagnostics, LLC | 1 | $15 |
How this compares
$2,665 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lamotrigine OdtLamotrigine | 15 | $4,586 |
| Oxcarbazepine | 21 | $1,475 |
| Levetiracetam | 31 | $1,356 |
| Gabapentin | 21 | $640 |
| Duloxetine Hcl | 24 | $622 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 20 | $570 |
| Memantine Hcl | 23 | $517 |
| Baclofen | 12 | $395 |
| Pregabalin | 18 | $275 |
| Escitalopram Oxalate | 20 | $169 |
| Donepezil Hcl | 35 | $141 |
| ClopidogrelClopidogrel Bisulfate | 11 | $102 |
Paid to pharmacies, not to this prescriber.
Other neurology in Ocoee
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.